Home
COVID-19
About Us
Products Center
Diagnostic Reagents
mRNA Raw Material
Diagnostic Equipment
News Center
Contact Us
Contact Information
Online Message
English
Company News
Industry News
Synthgene's 3 monkeypox virus detection kits have also been approved by the EU CE certification
On May 24, Nanjing Synthgene Medical Technology Co., Ltd.. (hereinafter referred to as "Synthgene") developed products "Monkeypox Virus Nucleic Acid Detection Kit (RT-PCR Method)", Monkeypox Virus Antigen Detection Kit (Colloidal Gold Method) ), monkeypox virus antibody detection kit (colloidal gold method) three products have obtained EU CE certificate at the same time, the approval of this series of products means that these kits can be sold in EU countries and countries that recognize EU CE certification, and can further It broadens the application fields of the company's products and responds more comprehensively to the needs of overseas markets.
25
2022
/
05
SARS-CoV-2 Nucleocapsid (N) Antigen Rapid Detection Kit obtained EU CE self-test certificate
At present, the SARS-CoV-2-related testing products independently developed and produced by Synthgene have been sold in more than 30 overseas countries, and were approved by the State Food and Drug Administration on April 1, 2022 (Registration Certificate No.: National Machinery Note 20223400427), officially launched!
20
Help fight the epidemic! Synthgene donates SARS-CoV-2 Antigen Rapid Detection Kit to Nanjing University
12
Synthgene Bio has successively completed A+ rounds of financing of over 300 million yuan, focusing on providing overall solutions for upstream raw materials in the field of life sciences!
Jiangsu Synthgene Biotechnology Co., Ltd. (hereinafter referred to asSynthgene Bio), the parent company of Nanjing Synthgene Medical Technology Co., Ltd., recently announced the completion of the A+ round of financing. This round of financing was jointly led by Qingchi Capital and LYFE Capital (Zhouling Capital). There are shareholders Sherpa Investment and Lenovo Star continue to make additional investments. Previously, the A1 round was jointly invested by Ruihua Capital, Sherpa Investment, and Legend Star. The two rounds of financing have accumulated a total of over 300 million yuan, and Life Capital served as the exclusive financial advisor for this financing.
11
04
Statement丨 Synthgene's SARS-CoV-2 Antigen Rapid Detection Kit is effective!
It has been verified that Synthgene's SARS-CoV-2 antigen kit is effective for the reported new coronavirus mutants!
10